Metabolic research · Evidence review
Retatrutide
Does a trial result validate a product sold online?
A selected obesity trial shows a weight-loss signal. That finding does not validate products sold outside clinical development.
What was actually studied
Adults with obesity or overweight and a weight-related condition in a randomized placebo-controlled trial.
What the paper found
- Participants assigned retatrutide lost more weight than those assigned placebo in the selected trial.
- Gastrointestinal effects and increased heart rate were reported.
Where the claim goes beyond the evidence
- This review covers the cited trial, not a complete account of the development program.
- Trial findings do not verify the contents or safety of an online vial.
Safety context
FDA states that retatrutide is not a component of an approved drug and cannot be used in compounding under federal law.
A research summary cannot establish that a product is suitable for you. Clinical decisions belong with a qualified health professional.
Read the original sources
- Original research — PubMed abstractTriple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. ↗
- FDA safety informationFDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss ↗